BLOOD TOXICITY;
CANCER IMMUNOTHERAPY;
COMORBIDITY;
DRUG EFFICACY;
DRUG FATALITY;
DRUG RESPONSE;
DRUG SAFETY;
DRUG TOLERABILITY;
ELDERLY CARE;
FUNCTIONAL DISEASE;
HUMAN;
INFECTIOUS COMPLICATION;
LARGE CELL LYMPHOMA;
LETTER;
MALNUTRITION;
MOLECULARLY TARGETED THERAPY;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGNOSIS;
UNSPECIFIED SIDE EFFECT;
VERY ELDERLY;
AGED, 80 AND OVER;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
LYMPHOMA, LARGE B-CELL, DIFFUSE;
PREDNISONE;
QUALITY OF LIFE;
TREATMENT OUTCOME;
VINCRISTINE;
EID: 79955468338PISSN: 14702045EISSN: NoneSource Type: Journal DOI: 10.1016/S1470-2045(11)70080-8Document Type: Letter
Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116.
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116:2040-2045.
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial
for the Groupe d'Etude de Lymphomes de l'Adulte (GELA) investigators, published online April 8.
Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011, for the Groupe d'Etude de Lymphomes de l'Adulte (GELA) investigators, published online April 8. 10.1016/S1470-2045(11)70069-9.
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the phase II EURO18 trial
Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the phase II EURO18 trial. Ann Oncol 2010, 21:1492-1499.
Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma
Gimeno E, Sanchez-Gonzalez B, Alvarez-Larran A, et al. Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. Leuk Res 2011, 35:358-362.
Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas
published online Jan 21.
Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 2011, published online Jan 21. 10.1093/annonc/mdq671.
